| Literature DB >> 22999905 |
Olivier Aubert1, Achille Aouba, Soizic Deshayes, Sophie Georgin-Lavialle, Philippe Rieu, Olivier Hermine.
Abstract
Erdheim-Chester disease is a rare non-langerhans cell histiocytosis characterized by infiltration of foamy CD68-positive but CD1a-negative macrophages and fibro-inflammatory lesions as retroperitoneal, periureteral areas or bones. Interferon-α therapy has been used as treatment but it had variable efficiency and limited tolerance. More recently, a recombinant form of interleukin-1 receptor antagonist (anakinra) was used with success but no skeletal radiological improvement was recorded. We report here a case of interleukin-1 receptor antagonist in the treatment of refractory bones infiltration in Erdheim-Chester disease. After 1 year of treatment, the positron emission tomography-computed tomography showed an outstanding response of the skeletal involvement with clearly lower and smaller hypermetabolism images.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22999905 DOI: 10.1016/j.jbspin.2012.07.005
Source DB: PubMed Journal: Joint Bone Spine ISSN: 1297-319X Impact factor: 4.929